Laser Photocoagulation and Photodynamic Therapy

  • G. SoubraneEmail author


First treatments available for exudative AMD,Aim of laser photocoagulation and photo­dynamic therapy: closure of choroidal new vessels to halt their progression


Optical Coherence Tomography Fluorescein Angiography Laser Photocoagulation Polypoidal Choroidal Vasculopathy Indocyanine Green Angiography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kang SJ, Schmack I, Benson HE, Grossniklaus HE (2007) Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases. Br J Ophthalmol 91:1602–1606PubMedCrossRefGoogle Scholar
  2. 2.
    Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:119–134CrossRefGoogle Scholar
  3. 3.
    Virgili G, Bini A (2007) Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 18(3):CD004763Google Scholar
  4. 4.
    Kaiser PK (2006) Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132–1142PubMedCrossRefGoogle Scholar
  5. 5.
    Kaiser PK, Visudyne In Occult CNV (VIO) study group (2009) Verteporfin PDT for subfoveal occult CNV in AMD: two year results of a randomized trial. Curr Med Res Opin 25:1853–1860PubMedCrossRefGoogle Scholar
  6. 6.
    Azab M, Boyer DS, Bressler NM, Visudyne in Minimally Classic Choroidal Neovascularization Study Group et al (2005) Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration. 2-year results of a randomized clinical trial. Arch Ophthalmol 123:448–457PubMedCrossRefGoogle Scholar
  7. 7.
    Augustin AJ, Scholl S, Kirchhof J (2009) Treatment of neovascular age-related macular degeneration: current therapies. Clin Ophthalmol 3:175–182PubMedCrossRefGoogle Scholar
  8. 8.
    Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U (2006) Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. doi: 10.1167/iovs.05-0354
  9. 9.
    Maberley D, Canadian Retinal Trials Group (2009) Photo­dynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 116:2149–2157PubMedCrossRefGoogle Scholar
  10. 10.
    Pauleikhoff D (2005) Neovascular age-related macular degeneration: Natural history and treatment outcomes. Retina 25:1065–1084PubMedCrossRefGoogle Scholar
  11. 11.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444PubMedCrossRefGoogle Scholar
  12. 12.
    Shah GK, Sang DN, Hughes MS (2009) Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina 29:133–148PubMedCrossRefGoogle Scholar
  13. 13.
    Emerson MV, Lauer AK (2008) Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2:377–388PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of OphthalmologyCreteil Eye Clinic, University HospitalCreteilFrance

Personalised recommendations